Washington DC: Moderna, the US-based biotech company submitted the results of its coronavirus vaccine trials to the country's Food and Drug Administration in order to obtain emergency use authorization for the vaccine.
Update: Moderna’s data for the Emergency Use Authorization request for mRNA-1273 has been submitted to the U.S. FDA.
— Moderna (@moderna_tx) November 30, 2020
Moderna tweeted on Monday regarding the updates and said that its vaccine efficacy was 94.1 percent but now it has reached 100 percent in severe coronavirus cases. It also said the vaccine is generally well tolerated and devoid of serious safety concerns. According to the current situation and as the things stand at present, candidates are expected to receive at least three promising vaccines for emergency use authorization from US health authorities in the coming weeks. Moderna stated that it plans to request an Emergency Use Authorization on Monday from the US FDA and conditional approval from the European Medicines Agency. After the final results from the late-stage study, it indicated that the Covid-19 vaccine candidate is 94.1 percent effective. The primary efficiency analysis of the "Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1 percent." The White House Press Secretary Kayleigh McEnany credited the latest development to "Trump's ingenuity at work."
Press Secretary said, "President Donald Trump's Operation Warp Speed has been an astounding success, delivering multiple vaccines in RECORD time. Today's announcement that Moderna will apply for a EUA after its vaccine demonstrated 94 percent efficacy is yet another example of Trump ingenuity at work!" The latest updates by Johns Hopkins University says that there are 13,511,194 COVID-19 cases and 267,792 deaths in the US alone.
Also Read:-
Bird flu wreaking havoc in this country, more than 18 lakh hens to die
